2019 UVA Controversies in Liver Disease and Transplantation

2019 UVA Cancer Center-Inova Schar Cancer Institute Oncology Update is organized by University of Virginia (UVA) and will be held on Nov 14, 2019 at Boar's Head Resort, Charlottesville, Virginia, United States of America.

Target Audience:
• Physicians
• Physician Assistants
• Nurse Practitioners
• Registered Nurses
• Pharmacists

Accreditation: 
The University of Virginia School of Medicine designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Virginia School of Medicine, as accredited provider, awards 6.50 hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to participants who successfully completes this education activity. The University of Virginia School of Medicine maintains a record of participations for six (6) years.

Program Overview:
• This conference will contain multiple simulated cases to re-enforce learning points in an optimized format for busy community oncologists.
• The cases presented in this conference are those most frequently encountered by community providers, thus it is critical that these providers follow best practices.

Educational Objectives:
The field of Oncology continues to develop and change both clinically and scientifically. The UVA Cancer Center and Inova Schar Cancer Institute are dedicated to educating health care providers involved in treating patients with a cancer diagnosis.

At the completion of the 2019 UVA Cancer Center/Inova Schar Cancer Institute Oncology Update, the participant should be able to understand and appreciate:

• Learners are expected to understand why pertuzumab may not be needed in low risk HER2+ breast cancer and to learn the paradigms for nonpertuzumab based adjuvant therapy regimens
• Learners are expected to understand why over use or under use of NGS in management of patients with squamous cell lung cancer may be problematic
• Learners are expected to recognize different subsets of mutations that confer resistance to commonly used TKI’s
• Learners are expected to understand and better appreciate early immunetoxicity events and to intervene earlier
• Learners are expected to gain a better understanding of immune related cardiac toxicity
• Learners are expected to better appreciate the role of interdisciplinary management of pancreatic cancer and evolving data on the role of radiotherapy
• Learners are expected to gain a better understanding of molecular diagnostics and impact of sidedness on selection of therapy
• Learners are expected to understand why the optimal management of oligometastatic disease requires multidisciplinary management and an understanding of evolving data in management of non-metastatic castration resistant disease
• Learners are expected to begin to discern differences in clinical trial results from recent phase III trials in the management of previously untreated metastatic kidney cancer.